Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes

Ermelindo C. Leal1,2, João Martins1,2, Paula Voabil1, Joana Liberal1, Carlo Chiavaroli3, Jacques Bauer3, José Cunha-Vaz2, António F. Ambrósio1,2,4

1Center of Ophthalmology and Vision Sciences, IBILI, Faculty of Medicine, University of Coimbra, Portugal; 2AIBILI, Coimbra, Portugal; 3OM PHARMA, Meyrin/Geneva, Switzerland; 4Center for Neuroscience and Cell Biology, University of Coimbra, Portugal.

Short running title: Calcium dobesilate and diabetic retinopathy

Corresponding author:
Dr. Ermelindo Carreira Leal
E-mail: eleal@ibili.uc.pt

Additional information for this article can be found in an online appendix at http://diabetes.diabetesjournals.org

Submitted 8 October 2009 and accepted 6 July 2010.

This is an uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association, publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org.
Objective: Calcium dobesilate (CaD) has been used in the treatment of diabetic retinopathy in the last decades, but its mechanisms of action are not elucidated. CaD is able to correct the excessive vascular permeability in the retina of diabetic patients and in experimental diabetes. We investigated the molecular and cellular mechanisms underlying the protective effects of CaD against the increase in blood-retinal barrier (BRB) permeability induced by diabetes.

Research Design and Methods: Wistar rats were divided into three groups: controls, streptozotocin (STZ)-induced diabetic rats and diabetic rats treated with CaD. The BRB breakdown was evaluated using Evans blue. The content or distribution of tight junction proteins (occludin, claudin-5 and ZO-1), ICAM-1 and p38 MAPK was evaluated by western blotting and immunohistochemistry. Leukocyte adhesion was evaluated in retinal vessels and in vitro. Oxidative stress was evaluated by the detection of oxidized carbonyls and tyrosine nitration. NF-kappaB activation was measured by ELISA.

Results: Diabetes increased the BRB permeability and retinal thickness. Diabetes also decreased occludin and claudin-5 levels, and altered the distribution of ZO-1, and occludin in retinal vessels. These changes were inhibited by CaD treatment. CaD also inhibited the increase in leukocyte adhesion to retinal vessels or endothelial cells, and ICAM-1 levels, induced by diabetes or elevated glucose. Moreover, CaD decreased oxidative stress, and p38 MAPK and NF-kappaB activation caused by diabetes.

Conclusions: CaD prevents the BRB breakdown induced by diabetes, by restoring tight junction protein levels and organization, and decreasing leukocyte adhesion to retinal vessels. The protective effects of CaD are likely to involve the inhibition of p38 MAPK and NF-kappaB activation, possibly through the inhibition of oxidative/nitrosative stress.

The blood-retinal barrier (BRB) breakdown is the hallmark of diabetic retinopathy (1). Alterations in BRB occur early in the progression of diabetic retinopathy and eventually lead to macular edema, which is responsible for vision loss (2). The increase in BRB permeability is associated with changes in the expression, content, phosphorylation and distribution of tight junction proteins in retinal vessels (3-7), and with increased vesicular transport mediated by endocytotic vesicles (8). Occludin and claudins are responsible for the direct cell-to-cell attachment in the tight junction barrier (9; 10) and are a crucial determinant of tight junction permeability properties in endothelial cells (11; 12). Claudin-5 is necessary to preserve the vascular barrier to small (<0.8 kDa) molecules in the brain (13), and it possibly also plays a similar role in the BRB. The zonula occludens proteins (ZO-1, 2, and 3) coordinate the assembly of the junctional complex and provide the interaction with components of the cytoskeleton (14), being also important for BRB function. Diabetes causes metabolic and physiologic abnormalities in the retina, and it appears that inflammation plays a critical role in the development of diabetic retinopathy. Those changes include the upregulation of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), intercellular adhesion molecule-1 (ICAM-1), caspase-1, vascular endothelial growth factor (VEGF), and nuclear factor kappa B (NF-kappaB), as
well as increased production of nitric oxide, prostaglandin E2, and cytokines (15; 16). We and others also demonstrated that the adhesion of leukocytes to retinal vessels is increased in the retinas of diabetic animals and this increase is correlated with changes in tight junction proteins and increased BRB permeability (4; 6; 8; 17; 18). The increase in leukostasis is also associated with an increase in the expression of ICAM-1 by retinal endothelial cells (18; 19). NF-kappaB regulates the expression of adhesion molecules, such as ICAM-1, and NF-kappaB activation has been correlated with the increase in leukostasis and BRB breakdown in diabetic rat retinas (20). Moreover, the p38 mitogen-activated protein kinase (p38 MAPK), a stress-activated serine/threonine protein kinase, is activated in response to proinflammatory cytokines and oxidative stress. The activation of p38 MAPK has been reported in the retinas of diabetic rats and is associated with BRB breakdown (21).

Calcium dobesilate (CaD) is considered an angioprotective drug and it has been used in the treatment of diabetic retinopathy and chronic venous insufficiency in several countries during the last decades (22; 23), but its efficacy in the treatment of diabetic retinopathy is still a matter of controversy. Several clinical studies have shown a slowdown of the progression of diabetic retinopathy after long-term oral treatment with CaD. Its clinical effectiveness occurs mainly through a correction of the excessive vascular permeability in the retina (24; 25). CaD decreases albumin leakage in the retina of diabetic animals (26), supporting its beneficial effects in BRB permeability. Other studies did not find beneficial effects in patients with diabetic retinopathy (27-29), but patients were treated with lower doses of CaD and for shorter periods (6-12 months). Recently, in a follow-up study (CALDIRET) of five years involving 635 patients with mild-to-moderate non-proliferative diabetic retinopathy, treatment with CaD was not able to reduce macular edema (30).

Despite the use of CaD in the treatment of diabetic retinopathy in the last decades, very low attention has been given to the molecular and cellular mechanisms underlying its vascular protective effects. In diabetic rats, the protective effect of CaD against BRB leakage was correlated with a decrease in the levels of advanced glycation end products (AGEs) and VEGF in the retina (26). It has been also suggested that the beneficial effects of CaD might be due to its antioxidant properties (31; 32). The present study aimed to clarify the molecular and cellular mechanisms underlying the protective effect of CaD against BRB permeability induced by diabetes. We evaluated for the first time whether CaD efficacy, in the early stages of diabetes, is linked to its effects on tight junctions and leukostasis. Moreover, its effects on the activation of p38 MAPK and NF-kappaB pathways, and on oxidative and nitrosative stress, were also addressed.

**RESEARCH DESIGN AND METHODS**

**Materials.** Materials and reagents used to carry out the experiments are described in the supplementary online Materials and Methods available at [http://diabetes.diabetesjournals.org](http://diabetes.diabetesjournals.org).

**Animal Model.** All procedures involving animals were conducted in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Diabetes was induced in 8-9 weeks old male Wistar rats with an intraperitoneal injection of streptozotocin (STZ; 65 mg/kg, in 10 mM citrate buffer, pH 4.5). Two days later, animals with blood glucose levels higher than 250 mg/dl were considered diabetic. The experiments were performed 1 month after diabetes induction.

The animals were divided into three groups (7-9 animals/group): control, diabetics, and diabetics treated with CaD (100 mg/kg/day;
Calcium dobesilate and diabetic retinopathy

orally given) during the last 10 days of diabetes. We also evaluated the effect of CaD on weight, blood glucose levels, retinal vascular permeability, retinal thickness, leukocyte adhesion to retinal vessels, tight junction protein content and localization, ICAM-1 content, formation of oxidized carbonyls and nitrotyrosine residues in proteins, and p38 MAPK and NF-kappaB activation. The results were similar to those obtained with control animals.

**Measurement of Blood-Retinal Barrier Permeability.** Blood-retinal barrier permeability was quantified with Evans blue, which binds to the plasma albumin, using the method described by Xu and colleagues (33), with some modifications. A more detailed description can be found in the supplementary online Materials and Methods.

**Retinal Thickness.** Retinal thickness was determined in retinal sections stained with hematoxylin/eosin as described in the supplementary online Materials and Methods.

**Visualization of Retinal Vessel Leakage.** Retinal vascular leakage was visualized using Evans blue. Under anesthesia, the rats were administered Evans blue (100 mg/kg) via tail vein, and kept on a warm pad for 60 min. The eyes were enucleated and fixed with 2% paraformaldehyde in PBS for 2 h. The retina was isolated, flat-mounted, and examined under a confocal microscope (LSM 510, Carl Zeiss, Gottingen, Germany) to check for Evans blue extravasation from retinal vessels.

**Western Blot Analysis.** Western blotting of cellular lysates was performed as detailed in the supplementary online Materials and Methods.

**Immunolocalization of Occludin, Claudin-5 and ZO-1 in Retinal Vessels.** The retinas were isolated (3 animals) and immersed in 2% paraformaldehyde for 2 x 5 min at RT. After washing 2 x 5 min in PBS with 0.3% Triton X-100, the retinas were immersed in blocking solution (6% goat serum) in PBS with 0.3% Triton X-100, for 30 min, and incubated for 3 days at 4°C with anti-occludin (1:100), anti-claudin-5 (1:00) or anti-ZO-1 (1:100) antibodies. After incubation, the retinas were washed for 24 h, and incubated with an Alexa 488-conjugated secondary antibody (goat anti-rabbit IgG, 1:250) in PBS with 0.3% Triton X-100. After incubation, the retinas were washed and flat mounted for visualization under a confocal microscope (LSM510, Carl Zeiss, Gottingen, Germany).

**Leukocyte Labelling.** Leukocyte suspensions were obtained from the spleen of normal Wistar rats. The cells were resuspended in 20 ml of complete medium [RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% sodium pyruvate, 4 mM L-glutamine, 1x nonessential amino acids (NEAA)]. To label the cells, 2 x 10^7 cells/ml were incubated with 40 μg/ml calcein-AM for 30 min at 37°C (34). Calcein-AM is nontoxic and has no effect on cell adhesion (35). The cells were washed, and 4 x 10^7 leukocytes in 200 μl RPMI were adoptively transferred into each rat through the tail vein.

**Leukocyte Adhesion to Retinal Vessels in Whole-Mounted Retinas.** Approximately 30 min after labelled leukocytes injection, Evans blue (100 mg/kg) was injected through the tail vein. Thirty minutes later, the animals were perfused with citrate-buffered 4% paraformaldehyde (37°C), and then the eyes were removed and immersed in 2% paraformaldehyde for 2 h at RT. The retinas were dissected, flat mounted and analysed by confocal microscopy (LSM 510, Carl Zeiss, Gottingen, Germany) to count the leukocytes adhering to retinal vessels.

**Retinal Endothelial Cell Culture.** Rat retinal endothelial cells (TR-iBRB2 cell line) (36) were cultured in low-glucose DMEM containing 10% FBS, 17.8 mM sodium bicarbonate, 0.1 mg/ml streptomycin and 100 units/ml penicillin. Cells were maintained at 33°C in a humidified atmosphere of 5% CO2/air. Cells were incubated with 24.5 mM glucose (30 mM final concentration), or with
Calcium dobesilate and diabetic retinopathy

Calcium dobesilate inhibits the increase in BRB permeability and retinal thickness induced by diabetes. Calcium dobesilate was orally administered (100 mg/kg/day) during the last 10 days of diabetes (30 days duration). After 1 month of diabetes, the weight gain in diabetic animals was significantly less when compared with controls (219.5 ± 6.6 g and 344.6 ± 5.8, respectively) and the blood glucose levels were significantly higher (496.2 ± 15.0 mg/dl and 96.3 ± 2.4 mg/dl, respectively). The weight and the blood glucose levels in diabetic animals treated with CaD were found to be similar to the values obtained for diabetic animals without treatment (217.3 ± 4.5 g and 470.9 ± 20.5 mg/dl, respectively) (Table 1).

Diabetes increased the BRB permeability in diabetic rats (4.0 ± 0.6 μg Evans blue/g wet weight retina) when compared with control animals (0.6 ± 0.1 μg Evans blue/g wet weight retina). In diabetic rats treated with CaD, there was a significant decrease in BRB permeability (1.2 ± 0.4 μg Evans blue/g wet weight retina) when compared to diabetic animals (Figure 1A). The blood vessel leakage was also visualized with Evans blue in retina flat mounts. In control retinas, Evans blue fluorescence was limited to the blood vessels. In diabetic rats, focal leakage of the dye from capillaries and larger vessels was detected, and the treatment with CaD prevented this effect (Figure 1B), corroborating the data obtained with the quantitative Evans blue assay. Moreover, CaD inhibited the increase in retinal thickness induced by diabetes. Diabetic retinas were significantly thicker than control retinas (153.0 ± 4.0 μm vs. 135.7 ± 5.0 μm), and no significant difference was found in retinal thickness between diabetic animals treated with CaD and control animals (145.2 ± 5.6 μm vs. 135.7 ± 5.0 μm) (Table 2).

RESULTS

Calcium dobesilate prevents the changes in the content and/or distribution of tight...
junction proteins in retinal vessels induced by diabetes. Diabetes induced a decrease in occludin and claudin-5 protein levels to 65.2% ± 7.5% and 63.2% ± 5.4% of the control, respectively. However, the total protein content of ZO-1 in retinal extracts of diabetic animals was not significantly different from the controls. Treatment of diabetic rats with CaD prevented the decrease in occludin and claudin-5 protein levels induced by diabetes (98.2% ± 9.7% and 92.4% ± 6.2% of the control, respectively; Figures 2A and 2B). In the retinas of CaD-treated diabetic animals, the protein levels of ZO-1 were also similar to controls (Figure 2C). Immunocytochemistry experiments confirmed these results (Figure 3). The immunoreactivity of occludin and claudin-5 clearly decreased in the retinal vessels of diabetic animals. In addition, the localization of occludin and ZO-1, but not of claudin-5, appears to be altered when compared to the retinas of control animals. In diabetic animals, occludin and ZO-1 immunostaining in retinal vessels is not so well defined at endothelial cell borders, when compared to control animals. Also, in several regions of the vasculature occludin and ZO-1 appear to accumulate in the cytosol of endothelial cells. The oral treatment with CaD prevented the decrease in occludin and claudin-5 immunoreactivity in retinal vessels induced by diabetes, as well as the alterations in occludin and ZO-1 localization in endothelial cells.

Caveolin-1 is an indicator of vascular permeability through a transcellular transport mechanism. Diabetes induces caveolin-1 overexpression in the rat retina (8). We found that diabetes increases caveolin-1 staining, mainly in ganglion cell layer. However, CaD treatment did not prevent the increase in caveolin-1 immunoreactivity (data not shown).

Calcium dobesilate inhibits leukocyte adhesion to retinal vessels induced by diabetes. In diabetic animals, there was an increase in the number of leukocytes adhering to retinal vessels (38 ± 4 leukocytes/animal) comparing to controls (16 ± 2 leukocytes/animal). In diabetic rats treated with CaD, there was a significant decrease in the number of adherent leukocytes (26 ± 2 leukocytes/animal) when compared to diabetic animals (Figure 4A).

Calcium dobesilate prevents the increase in leukocyte adhesion to retinal endothelial cells induced by high glucose. We also evaluated the effect of CaD on the adhesion of leukocytes to retinal endothelial cells (TR-iBRR2 cell line). We reported previously that exposure of retinal endothelial cells to elevated glucose (30 mM) for 4 days increases the adhesion of leukocytes to endothelial cells (18). As expected, the present data show that high glucose, but not mannitol (osmotic control), increased the adhesion of leukocytes to endothelial cells (128.7 ± 4.8% of the control). The exposure of endothelial cells to increasing concentrations of CaD (12.5, 25 and 50 μg/ml) for 4 days did not alter the adhesion of leukocytes (100.5 ± 3.5%, 96.3 ± 7.5% and 98.4 ± 9.8% of the control, respectively). However, 25 and 50 μg/ml of CaD, but not 12.5 mg/ml, totally prevented the increase in leukocyte adhesion induced by high glucose (98.7 ± 7.5% and 101.9 ± 7.8% of the control, for 25 μg/ml and 50 μg/ml, respectively; 126.8 ± 5.0% for 12.5 μg/ml) (Figure 4B).

Calcium dobesilate prevents the upregulation of ICAM-1 levels in retinal endothelial cells induced by diabetes or high glucose. The adhesion of leukocytes to retinal vessels is mediated by the interaction with ICAM-1, which is expressed in retinal endothelial cells. In the retinas of diabetic rats, the protein content of ICAM-1 increased to 136.4 ± 12.5% of the control. The upregulation of ICAM-1 induced by diabetes was prevented by CaD treatment (Figure 4C). Similarly, in
Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesilate and diabetic retinopathy

Calcium dobesitate reduces diabetes-induced oxidative and nitrosative stress. It has been claimed that CaD exerts its protective effects due to its antioxidant properties (26-32). Therefore, we evaluated the effects of CaD on the formation of oxidized carbonyl groups and on tyrosine nitration in retinal proteins. Oxidative injury to carbonyl residues significantly increased in diabetic retinas (176.2 ± 18.4 % of the control) in comparison with the controls, and CaD treatment prevented that increase (110.6 ± 19.3% of the control) (Figure 5A). Similarly, diabetes increased tyrosine nitration within retinal layers. The strongest immunoreactivity against nitrotyrosine residues was found within the ganglion cell layer (Figure 5B). Treatment with CaD prevented the increase in tyrosine residues nitration.

Calcium dobesilate decreases the activation of p38 MAPK and NF-kappaB induced by diabetes. Both p38 MAPK and NF-kappaB were found to be activated in diabetic retinas and their activation has been correlated with changes in BRB permeability (20; 21). The activation of p38 MAPK, which was evaluated by the ratio phospho-p38/p38, significantly increased in the retinas of diabetic animals (174.1 ± 29.9 % of the control) (Figure 6A). Diabetes also increased NF-kappaB activity (129.3 ± 8.4 % of the control) (Figure 6B). Treatment with CaD prevented the activation of p38 MAPK and NF-kappaB induced by diabetes (Figures 6A and 6B).

DISCUSSION

This is the first study clearly showing that CaD inhibits changes in tight junction proteins, ICAM-1 and leukocyte adhesion to retinal vessels, which are known to underlie the increase in BRB permeability. These findings were correlated with the inhibition of oxidative/nitrosative stress, and p38 MAPK and NF-kappaB activity.

The potential beneficial effects of CaD on BRB are still controversial. Several studies have reported vasoprotective effects of CaD in the early stages of diabetic retinopathy (22; 24; 25). For example, in a double-blind, placebo-controlled study, a positive effect of CaD (2000 mg daily for 2 years) was shown in patients with early diabetic retinopathy (25). Other studies have reported no beneficial effects of CaD in the retina of diabetic patients (27-29). In a recent study (CALDIRET) (30), where mild-to-moderate non-proliferative diabetic retinopathy patients were followed during five years, CaD failed to reduce diabetic macular edema. However, this study also shows that particular subgroups of patients, the treatment with CaD can be beneficial. It appears that the patients with accumulation of risk factors benefit with CaD. Altogether, these findings suggest that CaD might be effective in the early stages of the pathology, losing its efficacy in later stages (mild-to-moderate non-proliferative diabetic retinopathy), where macular edema might occur. In the later stages, CaD will possibly be effective only in some groups of patients. In animal models, where the duration of diabetes was relatively short, as is the case of this study, the beneficial effects of CaD on BRB are clear (26), supporting its use in the
Calcium dobesilate and diabetic retinopathy

early stages of the disease. In humans, the genetic background, environmental conditions and age are not as homogeneous as in animal models, and these factors certainly impact on the outcome of the study.

Diabetes decreased occludin and claudin-5 content, but not the content of ZO-1. In mice, we reported that diabetes decreased retinal ZO-1 levels after two weeks of diabetes (18). A decrease in retinal ZO-1 levels was also found in diabetic rats, although with a prolonged diabetes duration (17). However, we found that diabetes disorganized ZO-1 distribution in retinal vessels, in a similar way as for occludin. Occludin interacts with ZO-1 and it must dimerize to form a four-helix bundle structure with ZO-1 (37), which may account for a similar disorganization pattern for both proteins. The distribution of claudin-5 was not affected, at least for this time point. Previous studies also showed that diabetes reduces occludin levels in retinal vessels and disorganizes occludin in retinal vessels (5; 6; 18). Barber and colleagues did not find a reduction in claudin-5 levels (5), but they did not quantify claudin-5 levels in retinal extracts. Recently, two studies demonstrated that claudin-5 expression and protein content are decreased in the retinas of STZ diabetic rats (8; 17), but for longer periods of diabetes. Therefore, our data and these findings also point to an important role of claudin-5 in the BRB breakdown induced by diabetes.

CaD totally prevented the alterations in tight junction proteins, indicating that its protective effects against the increase in BRB permeability are due to its stabilizing effects on tight junction proteins (paracellular permeability). It has been claimed that the increase in vesicular transport (transcellular permeability) also contributes to the increase in BRB permeability (8). However, vesicular transport appears not to be affected by CaD, since it was not able to prevent the increase in caveolin-1 immunoreactivity induced by diabetes.

The increase in ICAM-1 expression and leukostasis is linked to the BRB breakdown (18; 19; 38; 39). In retinas, CaD totally prevented the increase in ICAM-1 levels, but the increase in leukocyte adhesion was only partially inhibited. This observation suggests that other players are involved in leukocyte adhesion, which are probably not substantially affected by CaD as ICAM-1 is. For instance, in endothelial cell cultures CaD per se decreased ICAM-1 levels. These data clearly suggest that CaD attenuates inflammatory processes occurring in diabetic retinas, which have been considered key players in BRB breakdown.

NF-kappaB activation is known to mediate the expression of cytokines and adhesion molecules, such as ICAM-1. In fact, it was found that NF-kappaB inhibition prevents the increase in ICAM-1 levels, leukocyte adhesion and BRB leakage in diabetic retinas (20). Our results also suggest that CaD prevented the increase in ICAM-1 levels, leukocyte adhesion and BRB leakage induced by diabetes, and this was correlated with the inhibition of NF-kappaB activation by CaD.

The protective effects of CaD against the BRB breakdown might be also due to its modulation of VEGF levels in the retina. VEGF is overexpressed in diabetic rat retinas and is involved in BRB leakage and leukocyte adhesion (40; 41). CaD treatment decreases VEGF content in diabetic rats and this observation was correlated with a decrease in BRB permeability (26).

Oxidative stress plays a role in leukocyte adhesion and BRB breakdown in the retinas of diabetic animals (18; 42). The protective effects of CaD can be explained by its antioxidant properties. CaD is effective in scavenging hydroxyl radicals in vitro (31). Moreover, CaD stabilizes the BRB in diabetic rats, apparently due to its antioxidant action (26), and markedly reduces retinal edema protecting diabetic rat retina against the oxidative stress induced by
Calcium dobesilate and diabetic retinopathy

ischemia/reperfusion (32). In this study, we confirmed that CaD decreases oxidative and nitrosative stress, since it completely prevented the increase in oxidized carbonyl groups and nitrotyrosine residues in proteins induced by diabetes. Since oxidative stress underlies inflammatory changes responsible for the BRB breakdown, our observations further support the idea that CaD vasoprotective effects might be mainly due to its antioxidant properties.

The activation of p38 MAPK and NF-kappaB pathways mediates BRB permeability in diabetic retinas (20; 21). Also, the inhibition of oxidative stress decreases p38 MAPK and NF-kappaB activation, and this was correlated with the prevention of early changes in diabetic retinas (20; 21; 43). In addition, evidences have shown that both p38 MAPK and NF-kappaB regulate tight junctions. The inhibition of p38 MAPK pathway improves the barrier function in epithelial cells (44) and prevents TNF-alpha-induced ZO-1 dislocation in bovine corneal endothelial cells (45). Furthermore, TNF-alpha-mediated NF-kappaB activation decreases ZO-1 levels and distribution in intestinal epithelial cells (46). In this work, we found that CaD decreased oxidative and nitrosative stress in diabetic retinas and this was correlated with the inhibition of p38 MAPK and NF-kappaB activation, as well as with the inhibition of changes in tight junction proteins, thus suggesting that the protective effects of CaD on paracellular permeability appear to be due to the inhibition of oxidative stress and consequently on p38 MAPK and NF-kappaB activation.

In summary, in this work we shed light into the molecular and cellular mechanisms underlying the protective effect of CaD against retinal vascular leakage induced by diabetes. CaD prevents changes in the content and distribution of tight junction proteins, as well as changes in ICAM-1 and leukocyte adhesion to retinal endothelial cells. These protective effects appear to be linked to its antioxidant effects, which prevent the activation of intracellular signaling pathways and transcription factors, such as p38 MAPK and NF-kappa B. These data reinforce the use of CaD in the treatment of diabetic retinopathy, particularly in the early stages of the disease.

**Author Contributions.** E.C. Leal researched data, contributed to discussion, wrote manuscript, reviewed/edited manuscript. J. Martins researched data, reviewed/edited manuscript. P. Voabil researched data, reviewed/edited manuscript. J.T. Liberal researched data, reviewed/edited manuscript. C. Chiavaroli contributed to discussion, reviewed/edited manuscript. J. Bauer contributed to discussion, reviewed/edited manuscript. J. Cunha-Vaz contributed to discussion, reviewed/edited manuscript. A.F. Ambrósio researched data, contributed to discussion, wrote manuscript, reviewed/edited manuscript.

**ACKNOWLEDGMENTS**
This work was supported by OM Pharma, Meyrin/Geneva, Switzerland.

**REFERENCES**
Table 1. Weight and blood glucose levels of control, diabetic and diabetic-treated animals.

<table>
<thead>
<tr>
<th></th>
<th>Weight (g)</th>
<th>Glycemia (mg/dl)</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>344.6 ± 5.8</td>
<td>96.3 ± 2.7</td>
<td>29</td>
</tr>
<tr>
<td>Diabetic</td>
<td>219.5 ± 6.6***</td>
<td>496.2 ± 15.0***</td>
<td>24</td>
</tr>
<tr>
<td>Diabetic + CaD</td>
<td>217.3 ± 4.5***</td>
<td>470.9 ± 20.5***</td>
<td>26</td>
</tr>
</tbody>
</table>

Diabetic animals (1 month diabetes duration) were treated with calcium dobesilate (100 mg/kg) in the last 10 days of diabetes. Weight (g) and blood glucose levels (mg/dl) were measured before animal sacrifice, and represent the mean ± SEM. ***p<0.01, significantly different from control; ANOVA (one-way) followed by Dunnett’s *post hoc* test. Legend: CaD – Calcium dobesilate.

Table 2. Retinal thickness measured in hematoxylin and eosin-stained retinas sections from control, diabetic and diabetic-treated animals.

<table>
<thead>
<tr>
<th>Retinal thickness (µm)</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>135.7 ± 5.0</td>
</tr>
<tr>
<td>Diabetic</td>
<td>153.0 ± 4.0*</td>
</tr>
<tr>
<td>Diabetic + CaD</td>
<td>145.2 ± 5.6</td>
</tr>
</tbody>
</table>

Diabetic animals (1 month diabetes duration) were treated with calcium dobesilate (100 mg/kg) in the last 10 days of diabetes. The eye sections, from the proximity of optical disc, were stained with hematoxylin/eosin. The retinal thickness was measured by image analysis of 5 fields per section, from six animals. The results represent the mean ± SEM. *p<0.05, significantly different from control; ANOVA (one-way) followed by Dunnett’s *post hoc* test. Legend: CaD – Calcium dobesilate.

Figure legends

Figure 1. Diabetes increases BRB permeability: protective effect of calcium dobesilate. (A) Quantitative measure of BRB permeability by quantification of extravasated Evans blue. Data are presented as µg of Evans blue per retina wet weight (g) and represent the mean ± SEM of 7-10 animals. **p<0.01, significantly different from control; ANOVA (one-way) followed by Dunnett’s *post hoc* test. #p<0.05, significantly different from diabetic; ANOVA (one-way) followed by Bonferroni’s *post hoc* test. (B) Representative images showing Evans blue fluorescence (red), allowing the detection of leaking sites (arrows) in retinal vessels. In the retina of control animals, Evans blue fluorescence is limited to the blood vessels, while in diabetic retinas the dye leak out of the vessels to the retinal tissue. Calcium dobesilate treatment prevents the leakage of Evans blue. Legend: CaD – Calcium dobesilate. Magnification: 100x; bar 200 µm.

Figure 2. Calcium dobesilate prevents the decrease in occludin and claudin-5 protein levels in the rat retinas induced by diabetes. ZO-1 levels were not significantly changed. Tight junction protein levels were assessed by western blotting. A representative western blot is shown above each graph. Data are presented as percentage of control and represent the mean ± SEM of 7-9 animals. *p<0.05, **p<0.01, significantly different from control; ANOVA (one-way) followed by Dunnett’s *post hoc* test. Legend: CaD – Calcium dobesilate.
Calcium dobesilate and diabetic retinopathy

Figure 3. Calcium dobesilate prevents the decrease in occludin and claudin-5 immunoreactivity, and the changes in occludin and ZO-1 distribution (arrows), in rat retinal vessels induced by diabetes. Magnifications: 200x (bar 100 μm) and 400x (bar 50 μm). Legend: CaD – Calcium dobesilate.

Figure 4. Diabetes and elevated glucose increase the number of leukocytes adhering to retinal vessels and retinal endothelial cells and the content of ICAM-1: protective effect of calcium dobesilate. (A) Quantification of leukocytes adhering to retinal vessels. Data are presented as number of adherent leukocytes to retinal vessels per rat (two retinas) and represent the mean ± SEM of 7 animals. (B) Quantification of leukocyte adhesion to retinal endothelial cells (TR-iBRB2 cell line) using a fluorometric assay. Data are presented as percentage of control and represent the mean ± SEM of 7-10 independent experiments. (C) The protein levels of ICAM-1 were evaluated in whole rat retinal extracts by western blotting. Data are presented as percentage of control and represent the mean ± SEM of 7 animals. (D) The protein levels of ICAM-1 were evaluated in whole extracts of rat retinal endothelial cell cultures (TR-iBRB2 cell line) by western blotting. Data are presented as percentage of control and represent the mean ± SEM of at least 4 independent experiments. *p<0.05, **p<0.01, significantly different from control; ANOVA (one-way) followed by Dunnett’s post hoc test. #p<0.05, ##p<0.01, ###p<0.001, significantly different from diabetic rat or high glucose condition; ANOVA (one-way) followed by Bonferroni’s post hoc test. Legend: CaD – Calcium dobesilate; HG – High Glucose (30 mM, for 4 days); CaD12.5, CaD25, CaD50 – Calcium dobesilate 12.5 μg/ml, 25 μg/ml, 50 μg/ml, respectively (4 days).

Figure 5. Calcium dobesilate prevents oxidative and nitrosative stress induced by diabetes. (A) The oxidized proteins were detected using an anti-DNP antibody by dot blot. A representative dot blot is shown above the graph. Data are presented as percentage of control and represent the mean ± SEM of 3-4 animals. *p<0.05, significantly different from control; ANOVA (one-way) followed by Dunnett’s post hoc test. (B) Representative images showing nitrotyrosine immunoreactivity (green), which allows the detection of nitrated tyrosine residues, and nuclear DAPI staining (blue). Magnification: 400x, bar 50 µm. Legend: CaD, Calcium dobesilate; GCL, ganglion cell layer; IPL, inner plexiform layer; OPL, outer plexiform layer; ONL, outer nuclear layer; CH, choroidal layer.

Figure 6. Calcium dobesilate inhibits the activation of p38 MAPK and NF-kappaB in diabetic rat retinas. (A) The activation of p38 MAPK was determined by western blotting, analyzing the phospho-p38/p38 MAPK ratio. A representative western blot is shown above the graph. (B) NF-kappaB activation was determined in retinal homogenates by ELISA (kit from Active Motif) using an antibody specific for the p65 subunit of NF-kappaB. A secondary antibody conjugated to horseradish peroxidase was used to quantifying spectrophotometrically the activated form. Data are presented as percentage of control and represent the mean ± SEM of 6-7 animals. *p<0.05, significantly different from control; ANOVA (one-way) followed by Dunnett’s post hoc test. #p<0.05, significantly different from diabetic animals; ANOVA (one-way) followed by Bonferroni’s post hoc test. Legend: CaD – Calcium dobesilate.
Figure 1

A

Evans blue leakage (µg Evans Blue/g retina wet weight)

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Diabetic</th>
<th>Diabetic+CaD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>0.5</td>
<td>4.2**</td>
<td>1.2#</td>
</tr>
<tr>
<td>SD</td>
<td>0.1</td>
<td>0.8</td>
<td>0.3</td>
</tr>
</tbody>
</table>

B

Control
Diabetic
Diabetic + CaD

Figure 2

A

Occludin
β-actin

B

Claudin-5
β-actin

C

ZO-1
β-actin
Figure 3

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Diabetic</th>
<th>Diabetic+CaD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Occludin</td>
<td><img src="image1.png" alt="Image" /></td>
<td><img src="image2.png" alt="Image" /></td>
<td><img src="image3.png" alt="Image" /></td>
</tr>
<tr>
<td>Claudin-5</td>
<td><img src="image4.png" alt="Image" /></td>
<td><img src="image5.png" alt="Image" /></td>
<td><img src="image6.png" alt="Image" /></td>
</tr>
<tr>
<td>ZO-1</td>
<td><img src="image7.png" alt="Image" /></td>
<td><img src="image8.png" alt="Image" /></td>
<td><img src="image9.png" alt="Image" /></td>
</tr>
</tbody>
</table>
Calcium dobesilate and diabetic retinopathy

Figure 4

A

Number of adherent leukocytes (per rat)

B

Invitro leukocyte adhesion (% of control)

C

RETINAS

ICAM-1

β-actin

D

ENDOTHELIAL CELLS

ICAM-1

β-actin

Figure 5

A

DNP immunoreactivity (% of control)

B

Control

Diabetic

Diabetic + CaD

GCL

IPL

OPL

ONL

CH
Figure 6

A

B

Phospho-p38MAPK

p38MAPK

phospho-p38/p38 MAPK

activation (% of control)

Control

Diabetic

Diabetic + CaD

Control

Diabetic

Diabetic + Cal

* 

#